Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome

Blanca E. Viramontes, Michael Camilleri, Sanna McKinzie, Darrell S. Pardi, Duane Burton, George M. Thomforde

Research output: Contribution to journalArticlepeer-review

94 Scopus citations


OBJECTIVE: To evaluate the influence of gender on the effect of a 5-HT3 antagonist, alosetron, 1 mg b.i.d., on GI and colonic transit in D-IBS. METHODS: Thirty patients (15 male, 15 female with D-IBS received 1 mg b.i.d. alosetron for 6 wk. Transit was measured by scintigraphy at baseline and at the end of treatment. RESULTS: Alosetron, 1 mg b.i.d., significantly retarded small bowel and, proximal and overall colonic transit in the 30 patients with D-IBS. The effect of alosetron on the primary endpoint, colonic geometric center at 24 h, was significantly greater in females than in males (p < 0.05). However, two females showed no slowing of colonic transit on treatment. Among male patients, two of 15 had a slowing of colonic transit at 24 h that was greater than the mean change in female patients, suggesting responsiveness to alosetron among a subgroup of males. CONCLUSION: A 5-HT3 antagonist, alosetron, significantly retards small intestinal and colonic transit in diarrhea-predominant IBS patients, with significantly greater female to male responsiveness. Gender partly contributes to differences in the serotonergic control of intestinal and colonic transit in patients with D-IBS.

Original languageEnglish (US)
Pages (from-to)2671-2676
Number of pages6
JournalAmerican Journal of Gastroenterology
Issue number9 SUPPL.
StatePublished - 2001

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Gender-related differences in slowing colonic transit by a 5-HT<sub>3</sub> antagonist in subjects with diarrhea-predominant irritable bowel syndrome'. Together they form a unique fingerprint.

Cite this